Company terms were last updated January 1, 2024 according to the website
Razia Hashmi, vice president of clinical affairs for the Blue Cross Blue Shield Association
10.3389/fpubh.2022.801619 Summary Keywords inhalation risk assessment, lung exposure modelling, lung toxicity, new approach methodologies, nonanimal testing, point of departure, bioactivity exposure ratio Citation de vila RI, Mller I, Barlow H, Middleton AM, Theiventhran M, Basili D, Bowden AM, Saib O, Engi P, Pietrenko T, Wallace J, Boda B, Constant S, Behrsing HP, Patel V and Baltazar MT (2025) Evaluation of a non-animal toolbox informed by adverse outcome pathways for human inhalation safety
If youre considering treatment with GLP-1 agonists, review your plans policies
Hartmans Five-Type Obesity Framework Excess intake relative to expenditure, without a significant underlying biological driver